Junshi Biosciences is developing antibodies to neutralize Covid-19
Shanghai-based drug developer Junshi Biosciences has teamed up with the Institute of Microbiology of the Chinese Academy of Sciences to develop new Covid-19 treatments using neutralizing antibodies —antibodies that can negate the biological effects of infectious agents in the body, such as viruses.
The two groups have been testing multiple strains of the antibodies in animal models and are in the process of building data so they can file IND applications with to local and overseas regulators.
“There has not yet been an effective antibody drug approved for treating the novel coronavirus in humans. We believe our collaboration with IMCAS will help accelerate the clinical development of an antibody therapy,” Junshi Biosciences CEO Ning Li said.
The two groups have been testing multiple strains of the antibodies in animal models and are in the process of building data so they can file IND applications with to local and overseas regulators.
“There has not yet been an effective antibody drug approved for treating the novel coronavirus in humans. We believe our collaboration with IMCAS will help accelerate the clinical development of an antibody therapy,” Junshi Biosciences CEO Ning Li said.
.png)
No hay comentarios:
Publicar un comentario